Similarly, in breast cancer patients with ERBB2 (also named HER-2/NEU) overexpression, the monoclonal antibody trastuzumab [11]–[13] and the small molecule inhibitor lapatinib [14] are effective. This evidence concerns the gene ERBB2 and breast carcinoma.